| BALIAKAS, P., T. MOYSIADIS, A. HADZIDIMITRIOU, A. XOCHELLI, S. JEROMIN, A. AGATHANGELIDIS, M. MATTSSON, L.A. SUTTON, E. MINGA, L. SCARFO, D. ROSSI, Z. DAVIS, N. VILLAMOR, H. PARKER, Jana KOTAŠKOVÁ, E. STALIKA, Karla PLEVOVÁ, L. MANSOURI, D. CORTESE, A. NAVARRO, J. DELGADO, M. LARRAYOZ, E. YOUNG, A. ANAGNOSTOPOULOS, K.E. SMEDBY, G. JULIUSSON, O. SHEEHY, M. CATHERWOOD, J.C. STREFFORD, N. STAVROYIANNI, C. BELESSI, Šárka POSPÍŠILOVÁ, D. OSCIER, G. GAIDANO, E. CAMPO, C. HAFERLACH, P. GHIA, R. ROSENQUIST and K. STAMATOPOULOS. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2019, vol. 104, No 2, p. 360-369. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.195032. |
Other formats:
BibTeX
LaTeX
RIS
@article{1531664,
author = {Baliakas, P. and Moysiadis, T. and Hadzidimitriou, A. and Xochelli, A. and Jeromin, S. and Agathangelidis, A. and Mattsson, M. and Sutton, L.A. and Minga, E. and Scarfo, L. and Rossi, D. and Davis, Z. and Villamor, N. and Parker, H. and Kotašková, Jana and Stalika, E. and Plevová, Karla and Mansouri, L. and Cortese, D. and Navarro, A. and Delgado, J. and Larrayoz, M. and Young, E. and Anagnostopoulos, A. and Smedby, K.E. and Juliusson, G. and Sheehy, O. and Catherwood, M. and Strefford, J.C. and Stavroyianni, N. and Belessi, C. and Pospíšilová, Šárka and Oscier, D. and Gaidano, G. and Campo, E. and Haferlach, C. and Ghia, P. and Rosenquist, R. and Stamatopoulos, K.},
article_location = {PAVIA},
article_number = {2},
doi = {http://dx.doi.org/10.3324/haematol.2018.195032},
keywords = {PREVIOUSLY UNTREATED PATIENTS; B-CELL RECEPTORS; STEREOTYPED IGHV3-21; GENOMIC ABERRATIONS; CLL; MUTATIONS; SURVIVAL; INDEX; GENE; CLASSIFICATION},
language = {eng},
issn = {0390-6078},
journal = {haematologica},
title = {Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia},
url = {http://www.haematologica.org/content/haematol/104/2/360.full.pdf},
volume = {104},
year = {2019}
}
TY - JOUR
ID - 1531664
AU - Baliakas, P. - Moysiadis, T. - Hadzidimitriou, A. - Xochelli, A. - Jeromin, S. - Agathangelidis, A. - Mattsson, M. - Sutton, L.A. - Minga, E. - Scarfo, L. - Rossi, D. - Davis, Z. - Villamor, N. - Parker, H. - Kotašková, Jana - Stalika, E. - Plevová, Karla - Mansouri, L. - Cortese, D. - Navarro, A. - Delgado, J. - Larrayoz, M. - Young, E. - Anagnostopoulos, A. - Smedby, K.E. - Juliusson, G. - Sheehy, O. - Catherwood, M. - Strefford, J.C. - Stavroyianni, N. - Belessi, C. - Pospíšilová, Šárka - Oscier, D. - Gaidano, G. - Campo, E. - Haferlach, C. - Ghia, P. - Rosenquist, R. - Stamatopoulos, K.
PY - 2019
TI - Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
JF - haematologica
VL - 104
IS - 2
SP - 360-369
EP - 360-369
PB - FERRATA STORTI FOUNDATION
SN - 03906078
KW - PREVIOUSLY UNTREATED PATIENTS
KW - B-CELL RECEPTORS
KW - STEREOTYPED IGHV3-21
KW - GENOMIC ABERRATIONS
KW - CLL
KW - MUTATIONS
KW - SURVIVAL
KW - INDEX
KW - GENE
KW - CLASSIFICATION
UR - http://www.haematologica.org/content/haematol/104/2/360.full.pdf
L2 - http://www.haematologica.org/content/haematol/104/2/360.full.pdf
N2 - Chronic lymphocytic leukemia (CLL) patients with differential somatic hypermutation status of the immunoglobulin heavy variable genes, namely mutated or unmutated, display fundamental clinico-biological differences. Considering this, we assessed prognosis separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015 patients, hypothesizing that the relative significance of relevant indicators may differ between these two categories. Within Binet A M-CLL patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset #2 membership were equivalently associated with the shortest time-to first -treatment and a treatment probability at Five and ten years after diagnosis of 40% and 55%, respectively; the remaining cases exhibited 5-year and 10-year treatment probability of 12% and 25%, respectively. Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q) and/or ST3B1 mutations were associated with the shortest time-to-First treatment (5- and 10-year treatment probability: 78% and 98%, respectively); in the remaining cases, males had a significantly worse prognosis than females. In conclusion, the relative weight of indicators that can accurately risk stratify early-stage CLL patients differs depending on the somatic hypermutation status of the immunoglobulin heavy variable genes of each patient. This finding highlights the fact that compartmentalized approaches based on immunogenetic features are necessary to refine and tailor prognostication in CLL.
ER -
BALIAKAS, P., T. MOYSIADIS, A. HADZIDIMITRIOU, A. XOCHELLI, S. JEROMIN, A. AGATHANGELIDIS, M. MATTSSON, L.A. SUTTON, E. MINGA, L. SCARFO, D. ROSSI, Z. DAVIS, N. VILLAMOR, H. PARKER, Jana KOTAŠKOVÁ, E. STALIKA, Karla PLEVOVÁ, L. MANSOURI, D. CORTESE, A. NAVARRO, J. DELGADO, M. LARRAYOZ, E. YOUNG, A. ANAGNOSTOPOULOS, K.E. SMEDBY, G. JULIUSSON, O. SHEEHY, M. CATHERWOOD, J.C. STREFFORD, N. STAVROYIANNI, C. BELESSI, Šárka POSPÍŠILOVÁ, D. OSCIER, G. GAIDANO, E. CAMPO, C. HAFERLACH, P. GHIA, R. ROSENQUIST and K. STAMATOPOULOS. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. \textit{haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2019, vol.~104, No~2, p.~360-369. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.195032.
|
